cardiac arrest and carbon monoxide poisoning: 100%
Hypoxemia: 10-15LPM via nrb
COPD: 0-2LPM via nc
INDICATIONS:Confirmed or expected hypoxemia, ischemic chest pain, respiratory insufficiency, prophylactically during air transport, confirmed or suspected co poisoning, all other causes of decreased tissue oxygenation, decreased level of consciousness.
CONTRA:Certain patients with COPD will not tolerate oxygen concentrations over 35%. Hyperventilation
SIDE EFFECTS:Decreased level of consciousness (COPD Patients) decreased respiratory drive in COPD patients, dry mucus membranes
Administer 2.5 mg dilute saline in nebulizer and administer over 10-15 min
Metered dose inhaler:1-2 inhalations; wait 5 min between inhalations
<20 kg:1.25 mg/dose via hand held nebulizer or mask over 20 min
>20 kg: 2.5 mg dose via hand held nebulizer over 20 min repeat once in 20 min
MOA:Selective beta-2 agonist that stimulates adrenergic receptors of the sympathomimetic nervous system. Results in smooth-muscle relaxation in the bronchial tree and peripheral vasculature.
Treatment of bronchospasm in patients with reversible obstructive airway disease (COPD/asthma) Prevention of exercise-induced bronchospasm.
Known prior hypersensitivity reactions to albuterol. Tachycardia, dysrhythmias, especially those caused by digitalis. Synergistic with other sympathomimetics.
SIDE EFFECTS:Often dose-related and include headache, fatigue, lightheadedness, irritability, restlessness, aggressive behavior, pulmonary edema, hoarseness nasal congestion, increased sputum, hypertension, tachycardia, dysrhythmias, chest pain, palpitations, nausea/vomiting, dry mouth, epigastric pain, and tremors
250-500 micro grams with hand held nebulizer every 20 min up to 3 times
Inhibits interaction of acetylcholine at receptor sites of bronchial smooth muscle, resulting in decreased cyclic guanosine monophosphate and bronchodilation
Persistent bronchospasm, COPD exacerbation
Hypersensitivity to ipratropium, atropine, alkaloids, peanuts